New India plant lifts Shasun's earnings; WTO may referee fight on Europe's API import rule;

> A $19 million investment in an API plant in Vizag, India, has helped Shasun Pharmaceuticals more than double its earnings in the last quarter. Story

> Swiss drugmaker Acino opened a new plant for transdermal therapeutic systems at the company's site in Miesbach, Germany. Release

> The FDA has OK'd a manufacturing change that will allow ViroPharma to scale up production of its injectable drug for hereditary angioedema, which causes swelling under the skin. Story

> India intends to set up pharmaceutical manufacturing in Sri Lanka as part of an effort to strengthen trade between the two countries. Story

> China and India may file a World Trade Organization complaint over the European Commission's pending rule that exporting countries must certify that APIs meet EC standards. Story

> Mylan ($MYL) says a subsidiary has started manufacturing 18 anti-retroviral products in India. Story

> And Finally... NPS Pharmaceuticals believes that its contract manufacturer will quickly resolve fill-and-finish issues that are keeping it from producing the drug to specifications so the company can submit its biologics license application for the bioengineered hormone Natpara by year's end. Story

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.